Company / Operating Cash Flow
Rani Therapeutics Holdings, Inc. Operating Cash Flow History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$35.5M
FY2025
5-year range
-$51.2M / -$15.0M
FY2021-FY2025
Trend
+30.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow returned to growth in FY2025 after 2 years of decline, reaching -$35M.
Based on SEC 10-K filings.
-$35M in FY2025.
Declined from -$32M to -$35M over the past 3 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow increased 30.7% year-over-year.
Company context
Key Data Points
- Altman Z-Score -1.77 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$35.5M | +30.7% |
| FY2024 | -$51.2M | -58.9% |
| FY2022 | -$32.2M | -115.5% |
| FY2021 | -$15.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026